Tyra Biosciences, Inc.
TYRA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TYRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TYRA
Tyra Biosciences, Inc. (TYRA) is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically defined cancers, with three product candidates in clinical development and no approved products.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.48B
Cash Runway
15.7 moLead Asset
dabogratinib (Phase 2)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 8 clinical trials · 1 catalyst for Tyra Biosciences, Inc..
Tyra Biosciences, Inc. (TYRA) is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically defined cancers, with three product candidates in clinical development and no approved products.
- Tyra Biosciences has three product candidates in clinical development, with other programs in preclinical or discovery stages [sec_mda · as of 2026-03-02].
- As of June 30, 2026, the company had cash, cash equivalents and marketable securities of $353.9 million and an accumulated deficit of $456.1 million [sec_mda · as of 2026-08-04].
- The company has not generated any revenue to date and has funded operations primarily through its initial public offering and private placements [sec_mda · as of 2025-08-14].
- Tyra has never completed any clinical trials or submitted an application for marketing approval for any product candidate [sec_mda · as of 2026-03-02].
What works
- Cash, cash equivalents and marketable securities of $353.9 million as of June 30, 2026, provides a substantial runway to advance clinical programs [sec_mda · as of 2026-08-04].
- The company is advancing three product candidates in clinical development, including dabogratinib, which is being evaluated in a Phase 2 trial for FGFR2-driven intrahepatic cholangiocarcinoma [sec_mda · as of 2025-08-14].
- Tyra's proprietary SNÅP platform supports ongoing research and development activities for future product candidates [sec_mda · as of 2025-08-14].
What to weigh
- Tyra has an accumulated deficit of $456.1 million as of June 30, 2026, and expects to continue incurring significant operating losses for the foreseeable future [sec_mda · as of 2026-08-04].
- The company has no products approved for commercial sale and has never completed a clinical trial or submitted a marketing application, making its business highly speculative [sec_mda · as of 2026-03-02].
- Future capital requirements are uncertain and depend on many factors, including the timing and costs of clinical trials, which could deplete resources sooner than expected [sec_mda · as of 2026-05-13].
From the filings
Quoted directly from source documents.
Tyra has three product candidates in clinical development and other programs in preclinical or discovery stages.
“We have three product candidates in clinical development. Our other development programs are either in preclinical development or in the drug discovery stage.”
SEC MD&A · March 2, 2026
As of June 30, 2026, Tyra had $353.9 million in cash, cash equivalents and marketable securities.
“As of June 30, 2026, we had cash, cash equivalents and marketable securities of $353.9 million.”
SEC MD&A · August 4, 2026
Tyra has an accumulated deficit of $456.1 million as of June 30, 2026.
“had an accumulated deficit of $456.1 million.”
SEC MD&A · August 4, 2026
Tyra has never completed any clinical trials or submitted a marketing application.
“As an organization, we have never completed any clinical trials or submitted an application for marketing approval and may be unable to do so for any of our product candidates.”
SEC MD&A · March 2, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · dabogratinib — Phase 2 Readout: dabogratinib — Top-line results from the Phase 2 trial of dabogratinib in FGFR2-driven intrahepatic cholangiocarcinoma are expected, which will provide initial efficacy and safety data.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Tyra has no products approved for commercial sale and has not generated any revenue to date [sec_mda · as of 2025-08-14].
- Significant accumulated deficit — Accumulated deficit of $456.1 million as of June 30, 2026, with expected continued losses [sec_mda · as of 2026-08-04].
- Clinical development uncertainty — The company has never completed a clinical trial, and results may not support regulatory approval [sec_mda · as of 2026-03-02].
- Capital depletion risk — Future capital requirements are uncertain and could deplete resources sooner than expected [sec_mda · as of 2026-05-13].
What to watch
- Phase 2 top-line data for dabogratinib in FGFR2-driven intrahepatic cholangiocarcinoma, expected by the end of 2026 [catalyst_timeline].
- Progress of the other two clinical-stage product candidates and any updates on preclinical programs [sec_mda · as of 2026-03-02].
- Changes in cash runway and operating expenses as clinical activities expand [sec_mda · as of 2026-08-04].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Tyra Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tyra Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
15.7 months
D/E 0.08 · 0% dilution
Lead: Phase 2
4 candidates
1 upcoming, next in ~123d
0 buys · 1 sell (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
160
Total value held
$2.20B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 12,198,625 | $467.2M |
| janus henderson group plc | 7,781,178 | $297.7M |
| fmr llc | 7,747,648 | $296.7M |
| farallon capital management llc | 3,580,818 | $137.1M |
| commodore capital lp | 2,475,000 | $94.8M |
| vanguard capital management llc | 2,251,940 | $86.2M |
| blackrock, inc. | 2,217,929 | $84.9M |
| bvf inc/il | 1,976,196 | $75.7M |
| caligan partners lp | 1,276,968 | $48.9M |
| state street corp | 1,216,078 | $46.6M |
Showing top 10 of 160 institutional holders of Tyra Biosciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 22.4%
- Days to cover
- 6.2
- Shares short
- 8,264,887
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TYRA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tyra Biosciences, Inc.?
Tyra Biosciences, Inc. (TYRA) is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically defined cancers, with three product candidates in clinical development and no approved products.
What is Tyra Biosciences, Inc.'s lead drug candidate?
Tyra Biosciences, Inc.'s most advanced tracked candidate is dabogratinib (Phase 2) for Low Grade Upper Tract Urothelial Carcinoma.
What is Tyra Biosciences, Inc.'s next catalyst?
Tyra Biosciences, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: dabogratinib" — expected December 31, 2026.
Who is the CEO of Tyra Biosciences, Inc.?
Dr. Todd Harris Ph.D. is the chief executive officer of Tyra Biosciences, Inc. (TYRA).
Where is Tyra Biosciences, Inc. headquartered?
Tyra Biosciences, Inc. (TYRA) is headquartered in Carlsbad, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.